ETF Sector Plus Strategy Overview

Dan Taylor | April 21, 2025

In the constantly evolving financial markets, static investment strategies often fall short. While many investors rely on traditional buy-and-hold approaches, market professionals recognize that not all sectors perform equally at the same time. This cyclical nature presents opportunities for those …


Why 2025 Has Been So Painful

Geoff Bysshe | April 20, 2025

Why The  Market Roller Coaster May Feel Much Worse Than Reported

The media will constantly remind us that the S&P is down about 10% and the Nasdaq is down about 13% for the year, but you may be feeling a …


Weekly Sector Analysis Routine: A Systematic Approach for Active Traders

Dan Taylor | April 18, 2025

The markets tell a story every week. Like chapters in an ever-evolving novel, sectors rise and fall, revealing critical insights for traders who know how to interpret them. However, without a structured analytical framework, these valuable signals often get lost …


The Economic Modern Family Breaks for Easter

Mish Schneider | April 16, 2025

Friday the markets are closed, and I am taking a brief hiatus beginning Thursday the 17th, back Monday the 21st. 

In the past week I covered the 20+ year long bonds, a few picks that are holding up very well, …


Creating a Sector-Based ETF Portfolio

Dan Taylor |

Financial markets rarely follow a straight path. Like the changing seasons, different economic conditions favor different industries at various times. Savvy investors recognize this cyclical pattern and use it to their advantage.

A sector-based ETF portfolio provides an effective way …


Worried About the Death Cross in MAGS (MAG7)?

Mish Schneider | April 15, 2025

Many analysts are still out there touting the great opportunity in the MAG7 stocks. 

For context, here are the top Holdings as of 04/14/2025 

While there is some green as of today, the overall ETF is down close to 1% …


After the Tariff Flush, a Fresh Look at AbbVie Pharma

Mish Schneider | April 14, 2025

In my 2025 Outlook, I picked AbbVie Pharmaceuticals as one to watch this year. 

Here is what I wrote: 

AbbVie (ABBV) AbbVie primarily works in immunology, oncology, neuroscience, eye care, and virology. It is also the parent company of Allergan, …


Risk Management for Self-Directed Sector Rotation Investors

Dan Taylor |

The markets don't reward the unprepared. While many investors focus on picking winning sectors or timing perfect entries, the truly successful ones know a different truth: masterful risk management often separates profitable investors from those who flame out. This reality …


Volume, Volatility & Gold Spike

Keith Schneider | April 13, 2025

This week’s commentary is the Big View bullets.

 

 

 

Every week we review the big picture of the market's technical condition as seen through the lens of our Big View data charts.

The bullets provide a quick summary …


Read and Hear About 3 Different Trade Ideas

Mish Schneider |

This past week, I got to talk about buys in a sea of sells. 

Amidst the falling dollar, rising yields, nasty trade war and poor earnings guidance, I went shopping. 

The first chart is of Uranium. 

In this segment with …